 Biotransformation
"Biotransformation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
| Descriptor ID |
D001711
|
| MeSH Number(s) |
G03.495.244 G07.690.812.097 G07.700.680.097
|
| Concept/Terms |
Activation, Metabolic- Activation, Metabolic
- Activations, Metabolic
- Metabolic Activations
- Metabolic Activation
|
Below are MeSH descriptors whose meaning is more general than "Biotransformation".
Below are MeSH descriptors whose meaning is more specific than "Biotransformation".
This graph shows the total number of publications written about "Biotransformation" by people in UAMS Profiles by year, and whether "Biotransformation" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2020 | 1 | 2 | 3 | | 2019 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2015 | 0 | 3 | 3 | | 2014 | 0 | 3 | 3 | | 2013 | 0 | 3 | 3 | | 2012 | 0 | 6 | 6 | | 2011 | 0 | 4 | 4 | | 2010 | 0 | 4 | 4 | | 2009 | 0 | 6 | 6 | | 2008 | 0 | 3 | 3 | | 2007 | 0 | 3 | 3 | | 2006 | 0 | 3 | 3 | | 2005 | 0 | 6 | 6 | | 2004 | 0 | 3 | 3 | | 2003 | 0 | 4 | 4 | | 2002 | 0 | 4 | 4 | | 2001 | 0 | 1 | 1 | | 2000 | 0 | 5 | 5 | | 1999 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1997 | 0 | 4 | 4 | | 1996 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1992 | 0 | 3 | 3 | | 1989 | 0 | 2 | 2 | | 1988 | 0 | 6 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Biotransformation" by people in Profiles over the past ten years.
-
Jackson KD, Argikar UA, Cho S, Crouch RD, Driscoll JP, Heck CJS, King L, Maw HH, Miller GP, Seneviratne HK, Wang S, Wei C, Zhang D, Khojasteh SC. Bioactivation and reactivity research advances - 2021 year in review. Drug Metab Rev. 2022 08; 54(3):246-281.
-
Khojasteh SC, Argikar UA, Driscoll JP, Heck CJS, King L, Jackson KD, Jian W, Kalgutkar AS, Miller GP, Kramlinger V, Rietjens IMCM, Teitelbaum AM, Wang K, Wei C. Novel advances in biotransformation and bioactivation research - 2020 year in review. Drug Metab Rev. 2021 08; 53(3):384-433.
-
Khojasteh SC, Driscoll JP, Jackson KD, Miller GP, Mitra K, Rietjens IMCM, Zhang D. Novel advances in biotransformation and bioactivation research-2019 year in review. Drug Metab Rev. 2020 08; 52(3):333-365.
-
Barnette DA, Schleiff MA, Osborn LR, Flynn N, Matlock M, Swamidass SJ, Miller GP. Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam. Toxicology. 2020 07; 440:152478.
-
Reisdorph NA, Hendricks AE, Tang M, Doenges KA, Reisdorph RM, Tooker BC, Quinn K, Borengasser SJ, Nkrumah-Elie Y, Frank DN, Campbell WW, Krebs NF. Nutrimetabolomics reveals food-specific compounds in urine of adults consuming a DASH-style diet. Sci Rep. 2020 01 24; 10(1):1157.
-
Khojasteh SC, Bumpus NN, Driscoll JP, Miller GP, Mitra K, Rietjens IMCM, Zhang D. Biotransformation and bioactivation reactions - 2018 literature highlights. Drug Metab Rev. 2019 05; 51(2):121-161.
-
Khojasteh SC, Miller GP, Mitra K, Rietjens IMCM. Biotransformation and bioactivation reactions - 2017 literature highlights *. Drug Metab Rev. 2018 08; 50(3):221-255.
-
Hartman JH, Martin HC, Caro AA, Pearce AR, Miller GP. Subcellular localization of rat CYP2E1 impacts metabolic efficiency toward common substrates. Toxicology. 2015 Dec 02; 338:47-58.
-
Hartman JH, Letzig LG, Roberts DW, James LP, Fifer EK, Miller GP. Cooperativity in CYP2E1 metabolism of acetaminophen and styrene mixtures. Biochem Pharmacol. 2015 Oct 01; 97(3):341-9.
-
Asakura M, Fujii H, Atsuda K, Itoh T, Fujiwara R. Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liver. Drug Metab Dispos. 2015 Apr; 43(4):477-84.
-
Yang X, Morris SM, Gearhart JM, Ruark CD, Paule MG, Slikker W, Mattison DR, Vitiello B, Twaddle NC, Doerge DR, Young JF, Fisher JW. Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates. PLoS One. 2014; 9(9):e106101.
-
Asakura M, Nakano M, Hayashida K, Fujii H, Nakajima M, Atsuda K, Itoh T, Fujiwara R. Human nitrilase-like protein does not catalyze the hydrolysis of vildagliptin. Drug Metab Pharmacokinet. 2014; 29(6):463-9.
-
Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatr Blood Cancer. 2014 Jun; 61(6):1055-62.
-
Zhu Y, Mapuskar KA, Marek RF, Xu W, Lehmler HJ, Robertson LW, Hornbuckle KC, Spitz DR, Aykin-Burns N. A new player in environmentally induced oxidative stress: polychlorinated biphenyl congener, 3,3'-dichlorobiphenyl (PCB11). Toxicol Sci. 2013 Nov; 136(1):39-50.
-
Udaondo Z, Molina L, Daniels C, Gómez MJ, Molina-Henares MA, Matilla MA, Roca A, Fernández M, Duque E, Segura A, Ramos JL. Metabolic potential of the organic-solvent tolerant Pseudomonas putida DOT-T1E deduced from its annotated genome. Microb Biotechnol. 2013 Sep; 6(5):598-611.
-
Pearce RE, Cohen-Wolkowiez M, Sampson MR, Kearns GL. The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep; 41(9):1686-94.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|